Display options
Cite
Burnett R, Ibañez CE, Pettersson PL, et al. Maintaining therapeutic activity in the operating room: compatibility of a gamma-retroviral replicating vector with clinical materials and biofluids. Mol Ther Methods Clin Dev. 2014;1:14024doi: 10.1038/mtm.2014.24.
Burnett, R., Ibañez, C. E., Pettersson, P. L., Chen, C. I., Parab, S., Huang, T., Robbins, J., Bankiewicz, K., Aghi, M., Logg, C., Kasahara, N., Pertschuk, D., Gruber, H. E., & Jolly, D. J. (2014). Maintaining therapeutic activity in the operating room: compatibility of a gamma-retroviral replicating vector with clinical materials and biofluids. Molecular therapy. Methods & clinical development, 114024. https://doi.org/10.1038/mtm.2014.24
Burnett, Ryan, et al. "Maintaining therapeutic activity in the operating room: compatibility of a gamma-retroviral replicating vector with clinical materials and biofluids." Molecular therapy. Methods & clinical development vol. 1 (2014): 14024. doi: https://doi.org/10.1038/mtm.2014.24
Burnett R, Ibañez CE, Pettersson PL, Chen CI, Parab S, Huang T, Robbins J, Bankiewicz K, Aghi M, Logg C, Kasahara N, Pertschuk D, Gruber HE, Jolly DJ. Maintaining therapeutic activity in the operating room: compatibility of a gamma-retroviral replicating vector with clinical materials and biofluids. Mol Ther Methods Clin Dev. 2014 Jun 25;1:14024. doi: 10.1038/mtm.2014.24. eCollection 2014. PMID: 26015967; PMCID: PMC4362351.
Copy Download .nbib Format: NLM
Share it on

Mol Ther Methods Clin Dev. 2014 Jun 25;1:14024. doi: 10.1038/mtm.2014.24. eCollection 2014.

Maintaining therapeutic activity in the operating room: compatibility of a gamma-retroviral replicating vector with clinical materials and biofluids.

Molecular therapy. Methods & clinical development

Ryan Burnett, Carlos E Ibañez, Pär L Pettersson, Ching-I Chen, Shraddha Parab, Tiffany Huang, Joan Robbins, Krystof Bankiewicz, Manish Aghi, Christopher Logg, Noriyuki Kasahara, Dan Pertschuk, Harry E Gruber, Douglas J Jolly

Affiliations

  1. Tocagen Inc., Bunker Hill St. , San Diego, CA, USA.
  2. Department of Neurological Surgery, University of California San Francisco (UCSF) , San Francisco, CA, USA.
  3. Department of Medicine, University of California Los Angeles (UCLA) , Los Angeles, CA, USA.

PMID: 26015967 PMCID: PMC4362351 DOI: 10.1038/mtm.2014.24

Abstract

Toca 511 is a novel retroviral replicating vector, encoding a modified yeast cytosine deaminase, administered to recurrent high grade glioma patients in Phase 1 trials by stereotactic, transcranial injection into the tumor or into the walls of the resection cavity. A key issue, with little published data, is vector biocompatibility with agents likely to be encountered in a neurosurgical setting. We tested biocompatibility of Toca 511 with: delivery devices; MRI contrast agents, including ProHance supporting coinjection for real time MRI-guided intratumoral delivery; hemostatic agents; biofluids (blood and cerebrospinal fluid); potential adjuvants; and a needleless vial adapter that reduces risk of accidental needle sticks. Toca 511 is stable upon thawing at ambient temperature for at least 6 hours, allowing sufficient time for administration, and its viability is not reduced in the presence of: stainless steel and silica-based delivery devices; the potential MRI contrast agent, Feraheme; ProHance at several concentrations; the hemostatic agent SURGIFOAM; blood; cerebrospinal fluid; and the needleless vial adapter. Toca 511 is not compatible with the hemostatic agent SURGICEL or with extended exposures to titanium-based biopsy needles.

References

  1. J Virol. 1998 Aug;72(8):6537-45 - PubMed
  2. Biotechnol Bioeng. 2003 May 5;82(3):321-9 - PubMed
  3. Virology. 2003 Mar 30;308(1):137-46 - PubMed
  4. Curr Opin Mol Ther. 2010 Dec;12(6):647-53 - PubMed
  5. Virology. 2001 Feb 1;280(1):124-31 - PubMed
  6. Cancer Res. 1963 Sep;23:1226-43 - PubMed
  7. Mol Ther. 2012 Sep;20(9):1689-98 - PubMed
  8. Expert Rev Neurother. 2009 Oct;9(10):1519-27 - PubMed
  9. J Virol. 1999 Aug;73(8):6708-14 - PubMed
  10. Anticancer Res. 2012 Jul;32(7):2439-53 - PubMed
  11. Mol Ther. 2010 Aug;18(8):1490-5 - PubMed
  12. Clin Cancer Res. 2006 May 15;12(10):3145-51 - PubMed
  13. Mol Ther. 2005 Nov;12(5):842-51 - PubMed
  14. Hum Gene Ther. 2000 Nov 20;11(17):2389-401 - PubMed
  15. Neuroimage. 2009 Aug;47 Suppl 2:T27-35 - PubMed
  16. Hum Gene Ther. 1999 Sep 20;10(14):2325-35 - PubMed
  17. Front Biosci. 2008 Jan 01;13:3083-95 - PubMed
  18. Transl Res. 2013 Apr;161(4):339-54 - PubMed
  19. Cell Transplant. 2000 Sep-Oct;9(5):585-94 - PubMed
  20. Nature. 1957 Mar 30;179(4561):663-6 - PubMed
  21. Neuro Oncol. 2012 Feb;14(2):145-59 - PubMed
  22. J Natl Cancer Inst. 1970 Apr;44(4):937-41 - PubMed
  23. J Gen Virol. 2006 May;87(Pt 5):1349-56 - PubMed
  24. PLoS One. 2009 Sep 29;4(9):e7218 - PubMed

Publication Types

Grant support